Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT03082755
PHASE4

Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease

Sponsor: University of Texas at Austin

View on ClinicalTrials.gov

Summary

Nighttime agitation in persons with Alzheimer's disease causes patient suffering, distresses caregivers, and often results in prescriptions for harmful antipsychotics. Effective treatments are lacking because of limited knowledge of the etiology of nighttime agitation. The investigators propose a clinical trial to better elucidate whether a sleep disorder, restless legs syndrome, may be a mechanism for nighttime agitation, and if treatment with gabapentin enacarbil (Horizant®) reduces nighttime agitation, improves sleep, reduces restless legs syndrome behaviors, and reduces antipsychotic medications.

Key Details

Gender

All

Age Range

55 Years - Any

Study Type

INTERVENTIONAL

Enrollment

156

Start Date

2017-07-01

Completion Date

2023-03-31

Last Updated

2022-05-18

Healthy Volunteers

No

Interventions

DRUG

Gabapentin Enacarbil

1 to 2 GEn tablets (300 milligrams per tablet) will be administered once a day in the evening (about 5pm) for 8 weeks.

DRUG

Placebo Oral Tablet

1 to 2 Placebo Oral Tablets will be administered once a day in the evening (about 5pm) for 8 weeks.

Locations (1)

The University of Texas at Austin

Austin, Texas, United States